FDA Approves Breakthrough Drug for Deadly Pancreatic Cancer, Doubling Survival Rates

A groundbreaking new drug called Rasonque (daraxonrasib) just received FDA approval for metastatic pancreatic cancer, the most common type of this deadly disease. A clinical trial found that patients receiving Rasonque lived more than double the time compared to those on standard chemotherapy alone, offering a rare glimmer of hope for a cancer that has historically been a death sentence.

Vital Signs

The numbers from the clinical trial paint a striking picture:

• **13...